Also known as: glucocorticoid
Prednisone is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive effects used across many disease categories. The RAYOS label includes broad uses spanning allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, pulmonary, renal, rheumatologic, infectious, endocrine, neoplastic, and transplant-related conditions. U.S. labeling shows initial approval in 1955.
A phase IIb trial demonstrated that low-dose IL-2 therapy produced dose-dependent improvements in SLE patients, with 69.7% achieving SRI-4 response at the highest dose versus 23.5% on placebo. A separate systematic review found IL-17 inhibitors remain potential SLE treatment options, though efficacy data are limited.
The FDA has approved three new targeted therapies for different stages of advanced prostate cancer: Truqap for PTEN-deficient tumors, rucaparib for BRCA-mutated castration-resistant disease, and Akeega for BRCA2-mutated castration-sensitive cancer.
Phase 3 trial data show daratumumab reduced relapse risk by 74% in NMOSD. Separately, the FDA accepted an NDA for iberdomide plus daratumumab/dexamethasone in relapsed/refractory multiple myeloma, with a PDUFA date of August 17, 2026.
PARP inhibitors remain strongest in BRCA1/2-altered tumors as use beyond that group has been uneven. In June 2025, the FDA narrowed Zejula’s first-line ovarian maintenance indication to HRD-positive tumors only.
Obinutuzumab demonstrated superior efficacy in two separate phase 3 trials for systemic lupus erythematosus and primary membranous nephropathy, with statistically significant improvements in remission rates and disease response measures.
Multiple pharmaceutical companies have initiated clinical trials for metastatic castration-resistant prostate cancer in February 2026, with over 180 companies developing 200+ pipeline therapies. Studies include combination therapies and novel drug candidates targeting advanced disease.
Amgen received FDA and European Commission approval for Uplizna to treat generalized myasthenia gravis in adults who are anti-AChR or anti-MuSK antibody positive, offering twice-yearly maintenance dosing after initial loading doses.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07594899 |
AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL |
NOT_YET_RECRUITING | PHASE2 |
| NCT07548606 |
A Drug-Drug Interaction Study of Itraconazole and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-017) |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT07535762 |
Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07535710 |
Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07493148 |
Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL |
RECRUITING | PHASE2 |
| NCT07451665 |
Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis |
NOT_YET_RECRUITING | PHASE4 |
| NCT07444710 |
Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma |
NOT_YET_RECRUITING | PHASE1 |
| NCT07431060 |
Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis |
RECRUITING | NA |
| NCT07426484 |
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy |
NOT_YET_RECRUITING | PHASE4 |
| NCT07418177 |
Study in Human iPSCs-derived RPE Cells Transplantation for Late-Stage AMD |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
